Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Justinian Lane

Justinian Lane Justinian C. Lane is a personal injury attorney who focuses his practice on helping individuals injured by prescription drugs and medical devices. His practice is nationwide and he welcomes e-mails at justinian@dangerousdrugs.us. His full biography is here.

Posts by Justinian Lane

Pradaxa lawsuit shows company wanted to bury damaging data

Posted in Pradaxa

It never ceases to amaze me that some people refuse to believe that corporations intentionally suppress safety information about their products due to marketing concerns.  Unfortunately, it keeps happening again, and again, and again.  This time, with Pradaxa: Publishing the research results, she warned, could make it “extremely difficult” for the company to defend its… Continue Reading

FDA won’t say which drugs on the market were approved based on fraudulent research

Posted in Drug Studies, FDA Regulation

This shows that the FDA is more interested in protecting pharmaceutical companies than patients.  Note how Woodcock doesn’t want to force new trials because that requires human experimentation, which has risk.  A smarter regulator would realize that the risks increase in proportion to the size of the user base of the drug.  And allowing any… Continue Reading

Washington court lets surgical robot lawsuit proceed

Posted in Surgical Robots

I knew there was a reason I got licensed to practice law in consumer-friendly Washington: A Washington state court yesterday denied Intuitive’s bid to throw out a lawsuit over the death of a patient operated on using the company’s da Vinci surgical system, according to court filings. The judge found the state’s product-liability laws require… Continue Reading

Pay to Delay vs. Generic Liability

Posted in Brand Name Liability, Legal Issues

So, the Supreme Court will decide two interesting cases.  The one below will decide whether or not a brand name manufacturer can simply pay generic companies not to bring generic drugs to market: WASHINGTON (AP) — Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay… Continue Reading

AAJ on Generic Preemption

Posted in FDA Regulation, Generic Drugs

Here’s a little more in-depth analysis of the generic drug argument before SCOTUS: Andre Mura, litigation counsel at the Center for Constitutional Litigation in Washington, D.C., said the government’s argument was troubling. “There were suggestions that the FDA shouldn’t be second-guessed, but as the Court said in Wyeth v. Levine, the FDA approval process does… Continue Reading

Manufacturer of surgical robots discouraged training of doctors

Posted in Devices, Surgical Robots

Just imagine the sleazy sales manager who wrote the e-mail below” Company e-mails introduced in a lawsuit filed against Intuitive in Kitsap County, Washington, suggest salesmen lobbied hospitals to scale back doctor training. One manager’s e-mail lauded a salesman for persuading a hospital that five supervised operations were too many. In another, a manager told… Continue Reading

More coverage of generic drug liability

Posted in Generic Drugs

More on generic liability:   During a one-hour oral argument justices questioned whether federal law, in this case the requirement that generics have same design as the name-brand version, prevents plaintiffs from making such claims under state law.   Some justices signaled concern about juries making sweeping judgments about the effectiveness of drugs while others… Continue Reading

Hip Replacements More Likely to Fail in Women than Men

Posted in DePuy Hip Replacement, Stryker Hip Replacement

This is from 02/18, but I forgot to post it back then.  Not sure what ramifications, if any, this will have for the various DePuy and Striker hip replacement lawsuits.  I’m certainly interested in speaking to anyone with a problem with their replacement hip regardless of gender. CHICAGO — Hip replacements are slightly more likely… Continue Reading

Former FDA Chief Wants To Gut Clinical Trials

Posted in Uncategorized

What is the “revolving door” I’m always talking about?  It’s this.  The former head of the FDA now is in private industry and he’s proposing drastic cuts to the clinical trial process.  Yet no one complains. The council’s report establishes an ambitious, yet reachable, national goal: doubling the current annual output of new medicines for… Continue Reading

Visit and Like our Facebook Page

Posted in DangerousDrugs.US

For someone with my background in tech, it’s kind of embarrassing that I haven’t been very engaged on Facebook.  But, that’s no longer the case.  We’ve had a Facebook page for a little while now, and today I put some effort into making it look a little more spiffy.  More importantly, it now has its… Continue Reading

Sequester may or may not slow down approvals of generic drugs

Posted in Generic Drugs, Politics

Could go either way.  Probably won’t have any effect on whether or not injured consumers can sue if they took generics. Hamburg said FDA has collected $125 million in GDUFA fees for 2013 so far. However, she noted, the budget situation and sequestration have “significant implications” for using generic user fees and budget dollars. Budget… Continue Reading

Our New Pharmacovigilance Specialist

Posted in DangerousDrugs.US

I’d like to introduce you to Jared Fink, who works for my firm as a Pharmacovigilance Specialist. What is a Pharmacovigilance Specialist, you ask? Well, every pharmaceutical company in the world has a team of folks who scour medical literature, the Internet, and other sources to look for signs that their drugs are causing harm…. Continue Reading

More on the Alabama generics ruling

Posted in Uncategorized

Behind a paywall, but still relevant: Business groups are urging Alabama’s highest court to reconsider its recent ruling that name-brand drug makers can be held liable for injuries caused by the generic versions of their products.   Source: Generic-Drugs Court Decision Irks Businesses – WSJ.com

Brand-name drug makers are not happy about Alabama Supreme Court ruling

Posted in Brand Name Liability, Legal Issues

Back in January the Alabama Supreme Court issued a ruling that enabled individuals who took generic drugs to sue the brand-name manufacturer.  Not surprisingly, the brand-name companies are not happy: BIRMINGHAM, Alabama — Brand name makers of a drug used to treat acid reflux and other digestive problems today asked the Alabama Supreme Court to… Continue Reading

Prozac can cause low birth weight

Posted in Prozac Birth Defects, SSRI Birth Defects

In 2003, a study by Dr. Victoria Hendrick et al. titled “Birth outcomes after prenatal exposure to antidepressant medication” was published in The American Journal of Obstetrics and Gynecology, aiming to evaluate the risk for congenital malformations in infants whose mothers used antidepressant medication during pregnancy. Using many different parameters and studying different antidepressant drugs… Continue Reading

Paxil Tied to Birth Defects

Posted in Paxil Birth Defects

In 2006, a research study by Bérard et al., a Canadian research team, titled “First Trimester Exposure to Paroxetine and Risk of Cardiac Malformations in Infants: The Importance of Dosage” was published in Birth Defects Research (Part B) that made several important conclusions about the safety of Paxil® use during pregnancy. In 1,403 infant-mother pairs… Continue Reading

Will consumers once again be able to sue generic drug manufacturers?

Posted in Generic Drugs, Preemption

Longtime readers of this (or any drug-related blog) know that the U.S. Supreme Court ruled that manufacturers of generic drugs cannot be sued for failure-to-warn claims.  The ruling created a legal injustice for those injured by generic drugs. While every plaintiff’s lawyer has secretly hoped that Congress would fix the law, we’re all savvy enough… Continue Reading